JPMorgan Securities Plc Form 8.5 (EPT/RI)-Clinigen Group plc_Amend (2102H)
04 Abril 2022 - 10:54AM
UK Regulatory
TIDMCLIN
RNS Number : 2102H
JPMorgan Securities Plc
04 April 2022
AMENDMENT
FORM 8.5 (EPT/RI)
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH
RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING
CAPACITY
Rule 8.5 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Name of exempt principal trader: J.P. Morgan Securities Plc
(b) Name of offeror/offeree in relation to whose relevant Clinigen Group plc
securities this form relates:
Use a separate form for each offeror/offeree
--------------------------------------------------
(c) Name of the party to the offer with which exempt principal Financial adviser to Triton Investment Management
trader is connected:
--------------------------------------------------
(d) Date dealing undertaken: 30 March 2022
--------------------------------------------------
(e) In addition to the company in 1(b) above, is the exempt N/A
principal trader making disclosures
in respect of any other party to this offer?
If it is a cash offer or possible cash offer, state "N/A"
--------------------------------------------------
2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER
Where there have been dealings in more than one class of
relevant securities of the offeror or offeree named in 1(b), copy
table 2(a), (b), (c) or (d) (as appropriate) for each additional
class of relevant security dealt in.
The currency of all prices and other monetary amounts should be
stated.
(a) Purchases and sales
Class of relevant Purchases/ sales Total number of Highest price per unit Lowest price per unit
security securities paid/received paid/received
0.1p ordinary Purchase 96,876 9.2350 GBP 9.2143 GBP
Sale 85,964 9.2350 GBP 9.2141 GBP
----------------- ------------------------ ----------------------- -----------------------
(b) Cash-settled derivative transactions
Class of relevant Product description Nature of dealing Number of reference Price per unit
security e.g. CFD e.g. opening/closing a securities
long/short position,
increasing/reducing a
long/short position
0.1p ordinary Equity Swap Decrease Long 12 9.2160 GBP
Decrease Short 182 9.2141 GBP
41,818 9.2170 GBP
1,713 9.2200 GBP
Increase Long 4,076 9.2193 GBP
Increase Short 25,000 9.2178 GBP
2,480 9.2181 GBP
430 9.2195 GBP
8,532 9.2201 GBP
4,583 9.2202 GBP
5,987 9.2205 GBP
15,581 9.2222 GBP
168 9.2338 GBP
Opening a long position 2,003 9.2212 GBP
2,069 9.2223 GBP
-------------------- ------------------------- ------------------------- ---------------
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of Product Writing, Number of Exercise Type Expiry date Option money
relevant description purchasing, securities price per e.g. paid/
security e.g. call selling, to which unit American, received per
option varying etc. option European unit
relates etc.
(ii) Exercise
Class of relevant Product description Exercising/ exercised Number of securities Exercise price per
security e.g. call option against unit
(d) Other dealings (including subscribing for new securities)
Class of relevant security Nature of dealing Details Price per unit (if applicable)
e.g. subscription, conversion
3. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal
or informal, relating to relevant securities which may be an inducement to deal or refrain
from dealing entered into by the exempt principal trader making the disclosure and any party
to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such
agreements, arrangements or understandings, state "none"
None
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the exempt
principal trader making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which
any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
None
Date of disclosure: 4 April 2022
Contact name: Alwyn Basch
--------------
Telephone number: 020 7742 7407
--------------
Public disclosures under Rule 8 of the Code must be made to a
Regulatory Information Service.
The Panel's Market Surveillance Unit is available for
consultation in relation to the Code's dealing disclosure
requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at
www.thetakeoverpanel.org.uk .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
FERUPUWACUPPGAC
(END) Dow Jones Newswires
April 04, 2022 11:54 ET (15:54 GMT)
Clinigen (LSE:CLIN)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Clinigen (LSE:CLIN)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
